Abstract
Congenital cytomegalovirus (cCMV) is the leading non-genetic cause of childhood sensorineural hearing loss. However, published descriptions of state-level approaches for integrating cCMV follow-up into existing Early Hearing Detection and Intervention (EHDI) and Newborn Blood Spot Screening (NBS) follow-up infrastructure are limited. In October 2024, hearing-targeted cCMV testing became required in Georgia through a change to the state’s rules and regulations. The Georgia Department of Public Health (DPH) developed a follow-up protocol built on three core components: cCMV was designated a notifiable condition, triggering electronic laboratory reporting (ELR) to DPH alongside provider and facility reporting requirements; medical follow-up for cCMV cases was integrated into the state’s existing NBS follow-up processes; and an audiologist-led protocol was established to facilitate timely diagnostic hearing evaluation and ongoing audiologic follow-up for confirmed cCMV cases. Between 10 October 2024 and 10 March 2026, DPH identified 103 newborns with an initial positive cCMV result. After excluding nine cases that did not enter the follow-up workflow at birth, 94 newborns were included in this analysis. Of these, 59 (62.8%) were laboratory-confirmed cCMV-positive, 33 (35.1%) were false positive, and 2 (2.1%) were presumptive positive. One newborn died before completing audiologic follow-up and was excluded from follow-up outcomes. Among the remaining 58 laboratory-confirmed cCMV cases requiring audiologic follow-up, 52 (89.7%) completed diagnostic Auditory Brainstem Response (ABR) evaluation and 6 (10.3%) were lost to follow-up; 14 of 52 (26.9%) evaluated newborns were diagnosed with sensorineural hearing loss (SNHL). This paper describes Georgia’s cCMV follow-up strategy and reports preliminary outcomes from the program’s first 18 months of implementation, offering an adaptable framework for integrating cCMV case follow-up and audiologic surveillance into existing state public health infrastructure.